GlassScriptPhysician profile
William Edward Barager
NPI 1962444638
$13,126.21
in general payments reported to CMS, 2019-2025
38 companies · $1,417 in 2025
The $1,417 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,143 · 2020: $3,125 · 2021: $751 · 2022: $1,474 · 2023: $3,179 · 2024: $2,037 · 2025: $1,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,472 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,083 · Education: $78.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,471.65 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,083.00 |
| Education | $78.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $3,873.39 | 2019-2024 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $1,977.57 | 2022-2025 | |
| Amgen INC. | $1,065.89 | 2019-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $902.50 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $827.65 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $789.69 | 2022-2025 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $423.58 | 2019-2025 | Veltassa |
| Glaxosmithkline, LLC. | $420.33 | 2021-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $283.37 | 2020-2025 | Acthar |
| Fresenius USA Marketing, INC. | $274.40 | 2020-2025 | Velphoro, Korsuva, Velphoro |
| Horizon Therapeutics Plc | $273.87 | 2019-2023 | Krystexxa |
| Novo Nordisk INC | $234.82 | 2019-2025 | Ozempic, Rybelsus, Rivfloza |
| Calliditas Therapeutics US INC. | $217.69 | 2022-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $181.86 | 2019-2021 | |
| Ardelyx, INC. | $181.68 | 2024-2025 | Ibsrela |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Barager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.